AZILSARTAN AS A POTENT ANTIHYPERTENSIVE DRUG WITH POSSIBLE PLEIOTROPIC CARDIOMETABOLIC EFFECTS: A REVIEW STUDY.

• Päätekijät: Georgiopoulos Georgios (Tekijä), Vasiliki Katsi (Tekijä), Dimitrios Oikonomou (Tekijä), Georgia Vamvakou (Tekijä), Evangelia Koutli (Tekijä), Aggeliki Laina (Tekijä), Constantinos Tsioufis (Tekijä), Petros Nihoyannopoulos (Tekijä), Dimitrios Tousoulis (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2016-08-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Hypertension related cardiovascular (CV) complications could be amplified by the presence of metabolic co-morbidities. Azilsartan medoxomil (AZL-M) is the eighth approved member of angiotensin II receptor blockers (ARBs), a drug class of high priority in the management of hypertensive su...